Use of PAM3CSK4 in the manufacture of a medicament for treating metabolic fatty liver, reducing accumulation of fat in the liver, eliminating fat from the liver of a patient
CN122229978APending Publication Date: 2026-06-19DASMAN DIABETES RESEARCH INSTITUTE KUWAIT
Patent Information
- Application Number
- CN202610383667.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-04-08
- Filing Date
- 2026-03-26
- Publication Date
- 2026-06-19
AI Technical Summary
Technical Problem
Currently, there are no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated fatty liver disease (MASLD). Although lifestyle modifications have benefits, most patients find it difficult to maintain them consistently.
Method used
Pam3CSK4 (Pam3CysSerLys4: a synthetic triacylated lipopeptide and TLR2/TLR1 ligand) was administered via intraperitoneal injection to reduce hepatic fat accumulation and improve fasting blood glucose levels.
Benefits of technology
Pam3CSK4 injection can effectively reduce liver fat accumulation in obese mice with fatty degeneration, completely restore normal liver function, prevent further fat uptake, and lower fasting blood glucose levels.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122229978A_ABST
Abstract
This application relates to the use of Pam3CSK4 in the preparation of a medicament for treating fatty liver disease associated with metabolic dysfunction, reducing hepatic fat accumulation, and / or eliminating hepatic fat in patients, which may include administering a therapeutically effective amount of Pam3CysSerlys4 (Pam3CSK4) to a patient in need. The therapeutically effective amount of Pam3CysSerlys4 may be administered via intraperitoneal (IP) injection.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Acetal stabilized prostaglandin compositions
US4358603A